GlassScriptPhysician profile
Vasu M Palli
NPI 1497013619
$10,927.25
in general payments reported to CMS, 2019-2025
32 companies · $4,729 in 2025
The $4,729 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $322 · 2021: $755 · 2022: $773 · 2023: $1,452 · 2024: $2,391 · 2025: $4,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,835 · Travel and Lodging: $2,728 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,835.11 |
| Travel and Lodging | $2,728.28 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,020.43 | 2022-2025 | General - Therapies, Watchman Flx, Cds Broad Portfolio Offering |
| Abbott Laboratories | $2,414.77 | 2019-2025 | Triclip, Aveir, Gallant |
| Atricure, INC. | $976.19 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $606.24 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $605.60 | 2022-2024 | Optimizer, Optimizer |
| Medtronic, INC. | $533.01 | 2021-2024 | Symplicity G3, Azure Xt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $418.96 | 2021-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $389.83 | 2019-2025 | |
| Irhythm Technologies, INC. | $231.09 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $223.68 | 2022-2024 | Farxiga, Wainua |
| Abiomed | $216.54 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.43 | 2023-2025 | Jardiance |
| Amgen INC. | $153.05 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $143.18 | 2019-2024 | Xarelto |
| W. L. Gore & Associates, INC. | $128.00 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $126.17 | 2024 | Inpefa |
| Pfizer INC. | $89.71 | 2020-2024 | |
| American Regent | $81.29 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $72.94 | 2021-2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $53.10 | 2024-2025 | Evkeeza |
| Edwards Lifesciences Corporation | $49.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.18 | 2021-2025 | |
| Cvrx, INC. | $33.63 | 2024 | Barostim Neo System |
| Preventice Services, LLC | $23.06 | 2021 | |
| Kestra Medical Technology Services, INC. | $18.41 | 2024 | Assure Wcd |
| Scpharmaceuticals INC. | $17.19 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $16.49 | 2024 | Arcalyst |
| Terumo Medical Corporation | $16.33 | 2024 | Glidewire, Progreat, Metacross Otw |
| Glaxosmithkline, LLC. | $16.08 | 2025 | Arexvy, Shingrix |
| Angiodynamics, INC. | $14.83 | 2020 | |
| Amarin Pharma, INC. | $14.25 | 2019 | |
| Astellas Pharma US INC | $14.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasu Palli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.